MRNS - Marinus plummets 78% as phase 3 interim analysis of ganaxolone disappoints
2024-04-15 11:00:02 ET
More on Marinus Pharmaceuticals
- Marinus Pharmaceuticals, Inc. (MRNS) Q4 2023 Earnings Call Transcript
- Marinus Pharmaceuticals Q4 2023 Earnings Preview
- Seeking Alpha’s Quant Rating on Marinus Pharmaceuticals
- Historical earnings data for Marinus Pharmaceuticals
- Financial information for Marinus Pharmaceuticals